By Regulatory Approvals — FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC Targeted Oncology
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 22, 2026.